Source author record

Hu Zhu

Hu Zhu appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

3works
5topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

3 published item(s)

preprint2022arXiv

Polarized image of synchrotron radiations of hotspots in Schwarzschilld-Melvin black hole spacetime

We revisit the innermost stable circular orbits (ISCOs) of charged particles and study the polarized images of synchrotron radiations emitted from such orbiting hotspots on the equatorial plane in Schwarzchild-Melvin black hole spacetime. We obtain a constraint on the magnetic field to retain ISCOs for charged particles. In particular, we identify a critical value for the strength of the magnetic field $B_c$ that the circular orbits can have positive and negative angular momentums above $B_c$ while only one branch survive below $B_c$. Furthermore, we investigate and discuss the primary and secondary images of circularly orbiting charged hotspots carrying the information of polarization directions observed by distant observers.

preprint2020arXiv

Bridge the Domain Gap Between Ultra-wide-field and Traditional Fundus Images via Adversarial Domain Adaptation

For decades, advances in retinal imaging technology have enabled effective diagnosis and management of retinal disease using fundus cameras. Recently, ultra-wide-field (UWF) fundus imaging by Optos camera is gradually put into use because of its broader insights on fundus for some lesions that are not typically seen in traditional fundus images. Research on traditional fundus images is an active topic but studies on UWF fundus images are few. One of the most important reasons is that UWF fundus images are hard to obtain. In this paper, for the first time, we explore domain adaptation from the traditional fundus to UWF fundus images. We propose a flexible framework to bridge the domain gap between two domains and co-train a UWF fundus diagnosis model by pseudo-labelling and adversarial learning. We design a regularisation technique to regulate the domain adaptation. Also, we apply MixUp to overcome the over-fitting issue from incorrect generated pseudo-labels. Our experimental results on either single or both domains demonstrate that the proposed method can well adapt and transfer the knowledge from traditional fundus images to UWF fundus images and improve the performance of retinal disease recognition.

preprint2020arXiv

Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics

The recent global pandemic of Coronavirus Disease 2019 (COVID-19) caused by the new coronavirus SARS-CoV-2 presents an urgent need for new therapeutic candidates. Many efforts have been devoted to screening existing drug libraries with the hope to repurpose approved drugs as potential treatments for COVID-19. However, the antiviral mechanisms of action for the drugs found active in these phenotypic screens are largely unknown. To deconvolute the viral targets for more effective anti-COVID-19 drug development, we mined our in-house database of approved drug screens against 994 assays and compared their activity profiles with the drug activity profile in a cytopathic effect (CPE) assay of SARS-CoV-2. We found that the autophagy and AP-1 signaling pathway activity profiles are significantly correlated with the anti-SARS-CoV-2 activity profile. In addition, a class of neurology/psychiatry drugs was found significantly enriched with anti-SARS-CoV-2 activity. Taken together, these results have provided new insights into SARS-CoV-2 infection and potential targets for COVID-19 therapeutics.